AP NEWS

Ischemia-Reperfusion Injury Drug Development Pipeline Analysis Report 2018 - ResearchAndMarkets.com

July 30, 2018

DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The “2018 Ischemia-Reperfusion Injury Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Ischemia-Reperfusion Injury Market” report has been added to ResearchAndMarkets.com’s offering.

Cardiac ischemia-reperfusion injury (IRI) is a heart related condition in which blood supply is restored to the tissue after some period of ischemia or absence of oxygen supply. The new supply causes additional complications such as inflammation, innate immunity, and oxidative stress instead of restoring regular function.

To assist researchers, investors and business development managers, the publisher has come up with a comprehensive report on Ischemia-Reperfusion Injury pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Ischemia-Reperfusion Injury pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Ischemia-Reperfusion Injury pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Companies Mentioned

Angion Biomedica Corp Armaron Bio Pty Ltd BioMedCore Inc Bolder Biotechnology Inc Catalyst Biosciences Inc Celdara Medical LLC CFM Pharma Holding BV Corline Biomedical AB Faraday Pharmaceuticals Glucox Biotech AB Ischemix Inc MallInckrodt Plc Miragen Therapeutics Inc NovelMed Therapeutics Inc Opsona Therapeutics Ltd Pharming Group NV Prolong Pharmaceuticals LLC Prothix BV Radikal Therapeutics Inc SBI Pharmaceuticals Co Ltd TheraSource LLC TRIM-edicine Inc X-In8 Biologicals Corp

Key Topics Covered:

1 Table of Contents

2 Ischemia-Reperfusion Injury Pipeline Analysis

3 Ischemia-Reperfusion Injury- Company Wise Pipeline Analysis

4 Ischemia-Reperfusion Injury R&D Pipeline Snapshots

5 Recent Developments in Ischemia-Reperfusion Injury Pipeline

6 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/6c25z3/ischemiareperfusi?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005337/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Cardiovascular Drugs ,Clinical Trials

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/30/2018 07:20 AM/DISC: 07/30/2018 07:21 AM

http://www.businesswire.com/news/home/20180730005337/en

AP RADIO
Update hourly